HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 TFA binds to the ligand-binding domain of angiotensin-converting enzyme-2 ( ACE2 ) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 TFA can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer [1] [2] [3].
In Vivo, HD5 (ectopic expression via lentiviral transduction; ~47 pg/mL secreted in cell supernatants) TFA significantly inhibits the oncolytic activity of PtDd-deficient adenoviruses (mut-Ad3GFP, wt-Ad5GFP) but not PtDd-producing adenovirus (wt-Ad3GFP) in CB17 mice subcutaneously injected with K562-HD5 cells, with PtDd able to reverse HD5-mediated inhibition of mut-Ad3GFP[3].
In Vitro, HD5 TFA binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells[1]. HD5 (20 µM) TFA binds to regions of HPV16 L1 and L2 capsid proteins[2]. HD5 (15 μM; 5 days) TFA significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP[3]. HD5 (0.1 μM) TFA binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay[3]. HD5 TFA significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected[3].
References:
[1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. doi: 10.3389/fphar.2020.575444.
[2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234.
[3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28.
In Vivo, HD5 (ectopic expression via lentiviral transduction; ~47 pg/mL secreted in cell supernatants) TFA significantly inhibits the oncolytic activity of PtDd-deficient adenoviruses (mut-Ad3GFP, wt-Ad5GFP) but not PtDd-producing adenovirus (wt-Ad3GFP) in CB17 mice subcutaneously injected with K562-HD5 cells, with PtDd able to reverse HD5-mediated inhibition of mut-Ad3GFP[3].
In Vitro, HD5 TFA binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells[1]. HD5 (20 µM) TFA binds to regions of HPV16 L1 and L2 capsid proteins[2]. HD5 (15 μM; 5 days) TFA significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP[3]. HD5 (0.1 μM) TFA binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay[3]. HD5 TFA significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected[3].
References:
[1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. doi: 10.3389/fphar.2020.575444.
[2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234.
[3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28.